Management of Stage 3C Triple-Negative Breast Cancer After Adjuvant Chemotherapy

Immediate Next Steps: Radiation Therapy

The National Comprehensive Cancer Network recommends that all chemotherapy regimens should be completed before initiating radiotherapy for locally advanced breast cancer 1, 2
Radiation therapy should be directed to the chest wall and regional lymph nodes (supraclavicular/infraclavicular and internal mammary nodes) given the stage 3C designation, which indicates extensive nodal involvement 1
The National Comprehensive Cancer Network suggests not to delay radiation beyond 6-8 weeks after completing chemotherapy to optimize local control 1

If neoadjuvant chemotherapy was given with residual disease at surgery, strongly consider adjuvant capecitabine based on the CREATE-X trial showing improved disease-free survival and overall survival in triple-negative breast cancer patients with residual disease 3, 4

Obtain germline BRCA1/2 mutation testing immediately if not already done, as this fundamentally changes treatment options if recurrence occurs 3, 4
BRCA mutation status determines eligibility for PARP inhibitors (olaparib or talazoparib) in the metastatic setting, which show improvement in progression-free survival over chemotherapy 3, 4
PD-L1 testing on the original tumor specimen should also be documented, as this guides immunotherapy eligibility if metastatic disease develops 4

Implement intensive surveillance with physical examination and symptom assessment every 1-2 months for the first 2 years, then every 3 months for years 3-5 5
Baseline imaging (chest CT, abdominal CT/ultrasound, bone scan) should be obtained 3-6 months post-treatment to establish a new baseline, given the high stage 5
Tumor markers (CA 15-3, CEA) may be monitored every 3 months, though these should not be the sole determinant for treatment decisions 5

If PD-L1 positive (≥1% tumor-infiltrating immune cells): Atezolizumab plus nab-paclitaxel is recommended, with median OS 25 months vs 15.5 months with chemotherapy alone, HR 0.62 4
If PD-L1 negative or unknown: Carboplatin plus nab-paclitaxel is recommended, with ORR 73%, median PFS 8.3 months, median OS 16.8 months 4
If BRCA1/2 mutation positive: PARP inhibitors (olaparib or talazoparib) are strongly preferred over chemotherapy, with doubled response rates and median PFS improvement from 4.2 to 7.0 months (HR 0.58) 3, 4
If ≥2 prior therapies for metastatic disease: Sacituzumab govitecan is recommended, with ORR 35% vs 5% with chemotherapy, median PFS 5.6 vs 1.7 months, HR 0.41 3, 4

Do not use combination chemotherapy in the metastatic setting unless rapid disease control is needed for symptomatic visceral crisis, as combinations increase toxicity without improving overall survival 5, 6
Do not rechallenge with platinum agents after progression on platinum-based therapy, as this increases toxicity without clear benefit 3
Do not delay radiation therapy to continue chemotherapy beyond standard regimens 1, 2